Get startedLog in
    Picture of Genor Biopharma Holdings logo

    6998 — Genor Biopharma Holdings Income Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeSmall CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for Genor Biopharma Holdings, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.

    2020
    December 31st
    2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue10.3015.90206
    Cost of Revenue
    Gross Profit7.74014.90205
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses2,913859799711279
    Operating Profit-2,903-859-783-711-72.6
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-3,036-866-732-677-35.1
    Provision for Income Taxes
    Net Income After Taxes-3,031-865-730-675-53
    Minority Interest
    Net Income Before Extraordinary Items
    Net Income-3,027-865-730-674-51.3
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Diluted Net Income-3,027-865-730-674-51.3
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-12.2-1.75-1.45-1.23-0.055